Abstracts tagged "cytokines"

Abstract Number: 1536 • 2019 ACR/ARP Annual Meeting
A Novel MK2 Inhibitor for the Treatment of Ankylosing Spondylitis and Other Inflammatory Diseases
Francisco Ramírez-Valle¹, Mary Adams ¹, Lisa Beebe ², Jian Chen ¹, Claudio Chuaqui ¹, Jamie Connarn ¹, Alan Corin ¹, Karen Dingley ¹, J. Michael Ellis ¹, Rajula Gaur ¹, Lawrence Hamann ¹, John Malona ¹, Kofi Mensah ¹ and Maria Palmisano ¹, ¹Celgene Corporation, Summit, NJ, ²Celgene Corporation, Cambridge, MA
Background/Purpose: Post-transcriptional control of cytokine and chemokine gene expression is an important checkpoint during inflammation. The MAPKAPK2 (MK2) pathway in particular is critical in regulating…
Abstract Number: 1703 • 2019 ACR/ARP Annual Meeting
Increased Levels of IL-2 and IL-4 Promote Th17/Treg Immune Imbalance in Patients with Behcet’s Disease
Yue Liu¹, Yan Yang ¹, Rui Su ², Xinyu Zheng ³, Xiao-feng Li ⁴ and Cai-hong Wang ⁵, ¹Department of Rheumatology, the Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China (People's Republic), ²Department of Rheumatology, the Second Hospital of Shanxi Medical University, Tai yuan, Shanxi, China (People's Republic), ³Department of Rheumatology, the Second Hospital of Shanxi Medical University, Taiyuan , Shanxi, China, Tai Yuan, China (People's Republic), ⁴The Second Hospital of Shanxi Medical University, Taiyuan, China (People's Republic), ⁵The Second Hospital of Shanxi Medical University, Tai Yuan, China (People's Republic)
Background/Purpose: Behcet’s disease(BD) is a multisystem inflammatory disorder of unknown etiology.Improved understandings indicate the Th17/Treg immune imbalance may play a critical role in BD's pathogenesis,…
Abstract Number: 1764 • 2019 ACR/ARP Annual Meeting
CCL25, a Novel Fibroblast and Macrophage Chemoattractant That Potentiates RA Bone Erosion
Sadiq Umar¹, Katrien Raemdonck ¹, Karol Palasiewicz ¹, Michael Volin ², Shiva Arami ¹, Suncica Volkov ¹, Nadera Sweiss ¹, M Amin ³ and Shiva shahrara ¹, ¹University of Illinois at chicago, Chicago, IL, ²Department of Microbiology & Immunology, Midwestern University, Downer Grove, IL, ³University of Michigan, Ann Arbor, MI
Background/Purpose: Background/Purpose: CCL25 and its receptor CCR9 have been detected in the inflamed joint; however their role is undefined in rheumatoid arthritis (RA). Hence studies…
Abstract Number: 1772 • 2019 ACR/ARP Annual Meeting
Chronotherapy Using Baricitinib Attenuates Collagen-induced Arthritis in Mice
Arisa Yaekura¹, Kanta Morii ², Yuto Oketani ³, Ikumi Okumura ², Kenta Kaneshiro ⁴, Kohsuke Yoshida ², Yoshiko Kawasaki ⁵, Nao Shibanuma ⁵, Yoshitada Sakai ⁶ and Akira Hashiramoto ², ¹Kobe University Graduate School of Health Sciences, Kawanishi, Hyogo, Japan, ²Kobe University Graduate School of Health Sciences, Kobe, Hyogo, Japan, ³Kobe University Graduate School of Health Sciences, Himeji, Hyogo, Japan, ⁴Kobe University Graduate School of Health Sciences, Osaka, Osaka, Japan, ⁵Kobe Kaisei Hospital, Kobe, Hyogo, Japan, ⁶Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan
Background/Purpose: Diurnal variations are observed in symptoms of rheumatoid arthritis (RA). Among them, “morning stiffness of joints” is closely reflects the daily medical condition of…
Abstract Number: 2418 • 2019 ACR/ARP Annual Meeting
Tofacitinib Inhibits Increased Inflammatory Marker Expression in a Human Salivary Cell Line Deficient in Autophagy: A Model of Sjögren’s Syndrome
María José Barrera ¹, Sergio Aguilera², Patricia Carvajal ³, Isabel Castro ⁴, Sergio González ⁵, Claudio Molina ¹, Soledad Matus ⁶, Daniela Jara ³ and María Julieta González ³, ¹Facultad de Odontología, Universidad San Sebastián, Santiago, Chile, ²Clínica INDISA, Santiago, Chile, ³ICBM, Facultad de Medicina, Universidad de Chile, Santiago, Chile, ⁴Departamento Tecnología Médica, Universidad de Chile, Santiago, Chile, ⁵Escuela de Odontología, Universidad Mayor, Santiago, Chile, ⁶Fundación Ciencia & Vida, Santiago, Chile, Santiago, Chile
Background/Purpose: Sjögren’s syndrome (SS) is an immune-mediated exocrinopathy, where defects in autophagy could contribute to the pathogenesis. Minor labial salivary glands (MLSG) of primary SS…
Abstract Number: 47 • 2018 ACR/ARHP Annual Meeting
Analysis of the Role of RORγt+Foxp3+ T Regulatory 17 (Tr17) Cells in Murine Autoimmune Arthritis Model
Kotona Furuyama¹, Yuya Kondo¹, Masaru Shimizu², Iizuka Akira¹, Masahiro Yokosawa¹, Seiji Segawa¹, Hiroto Tsuboi¹, Isao Matsumoto¹ and Takayuki Sumida¹, ¹Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ²Internal Medicine, Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan
Background/Purpose: RORγt+Foxp3+ regulatory T (Treg) cells, designated as Tr17 is one of the new subset of Treg cells, having the potential to regulate the development…
Abstract Number: 1088 • 2018 ACR/ARHP Annual Meeting
Pro-Inflammatory and Regulatory Soluble Mediator Pathways Vary between African American and European American SLE Patients
Samantha Slight-Webb¹, Miles C. Smith¹, Holden T. Maecker², Paul J. Utz³, Joel M. Guthridge¹ and Judith A. James⁴, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Stanford University, Stanford, CA, ³Medicine, Stanford University School of Medicine, Stanford, CA, ⁴Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease that primarily affects women, and is associated with periods of elevated and suppressed clinical symptoms. SLE…
Abstract Number: 2510 • 2018 ACR/ARHP Annual Meeting
A Phase IIa Mechanistic Study of Anti-GM-CSF (GSK3196165) with Methotrexate Treatment in Patients with Rheumatoid Arthritis (RA) and an Inadequate Response to Methotrexate
Mark C. Genovese¹, Mario Berkowitz², Philip G. Conaghan³, Katherine Davy⁴, David Inman⁵, Elena Fisheleva^6,7, Anubha Gupta⁶, Robert Janiczek⁶, Mark Layton⁸, Nina Mitchell^6,7, Jatin Patel⁹, Julia E. Smith¹⁰, Russell Williamson⁵ and Paul-Peter Tak¹¹, ¹Stanford University Medical Center, Palo Alto, CA, ²Leon Medical Research, Lauderdale Lakes, FL, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁴Statistics, GlaxoSmithKline, Stevenage, UK, Stevenage, United Kingdom, ⁵GlaxoSmithKline, Stockley Park, United Kingdom, ⁶GlaxoSmithKline, Stevenage, United Kingdom, ⁷Currently at Biomarin UK Ltd, London, United Kingdom, ⁸ImmunoInflammation, ImmunoInflammation, GlaxoSmithKline, Stevenage, UK, Stevenage, United Kingdom, ⁹ImmunoInflammation, GlaxoSmithKline, Stevenage, UK, Stevenage, United Kingdom, ¹⁰Immunoinflammation TA, GSK Medicines Research Centre, Stevenage, Hertfordshire, United Kingdom, ¹¹GlaxoSmithKline, Stevenage, Hertfordshire, United Kingdom
Background/Purpose: GSK3196165 is a high-affinity anti-GM-CSF cytokine IgG mAb currently in development for RA, with reported efficacy using IV dosing. This study evaluated the effects…
Abstract Number: 59 • 2018 ACR/ARHP Annual Meeting
Elucidating the Expression and Role of Heparan Sulfate Proteoglycan Editing Sulfatases in Human Rheumatoid Arthritis Synovium and a Rat Adjuvant-Induced Arthritis Model
Ruby J. Siegel¹, Solomon A. Agere¹, Anil K. Singh¹ and Salahuddin Ahmed^2,3, ¹Washington State University, Department of Pharmaceutical Sciences, College of Pharmacy, Spokane, WA, ²Department of Pharmaceutical Sciences, Washington State University, College of Pharmacy, Spokane, WA, ³Division of Rheumatology, University of Washington, Division of Rheumatology, School of Medicine, Seattle, WA
Background/Purpose: Syndecans are cell-surface heparan sulfate proteoglycans (HSPGs) that modulate the receptor/ligand binding of chemokines, cytokines, and growth factors in order to facilitate cellular signaling.…
Abstract Number: 1335 • 2018 ACR/ARHP Annual Meeting
Extracellular Vesicles Induce Pro-Inflammatory Cytokines in Dermatomyositis
Krisha Desai^1,2, Majid Zeidi^3,4, Ming-Lin Liu^1,2 and Victoria P. Werth^1,2, ¹Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²Department of Dermatology, Corporal Michael J. Crescenz VAMC, Philadelphia, PA, ³University of Pennsylvania, Philadelphia, PA, ⁴Philadelphia Veterans Affairs Medical Center, Philadelphia, PA
Background/Purpose: Extracellular vesicles (EVs) are micron-scale bilayer membrane vesicles released from almost all cell types under activation or apoptosis. They have been detected in various…
Abstract Number: 2519 • 2018 ACR/ARHP Annual Meeting
Exposure-Efficacy Analysis in DMARD Inadequate Response Rheumatoid Arthritis Patients Treated with GSK3196165 Along with Methotrexate
Anubha Gupta¹, Chiara Zecchin¹, Elena Fisheleva^1,2, Mark Layton³ and Stefano Zamuner⁴, ¹GlaxoSmithKline, Stevenage, United Kingdom, ²Currently at Biomarin UK Ltd, London, United Kingdom, ³ImmunoInflammation, ImmunoInflammation, GlaxoSmithKline, Stevenage, UK, Stevenage, United Kingdom, ⁴Clinical Pharmacology, GlaxoSmithKline, Stevenage, United Kingdom
Background/Purpose: GSK3196165 is an anti-GM-CSF mAb being developed for RA. In a phase IIb dose-finding study (NCT02504671), RA patients with inadequate response to methotrexate were…
Abstract Number: 96 • 2018 ACR/ARHP Annual Meeting
The Liver X Receptor Modulates Inflammatory Cytokines Based on Lxrα Polymorphism in Monocyte-Derived Macrophages and Patients with Systemic Lupus Erythematosus
Chang-Hee Suh¹, Wook-Young Baek², Hyoun-Ah Kim³ and Ju-Yang Jung², ¹Rheumatology, Ajou University School of Medicine, Suwon, Korea, Republic of (South), ²Ajou University School of Medicine, Suwon, Korea, Republic of (South), ³Department of Rheumatology, Ajou University School of Medicine, Suwon, Korea, Republic of (South)
Background/Purpose: Liver X receptors (LXRs) have emerged as important regulators of inflammatory gene expression. Previously, we had reported that an LXRα gene promoter polymorphism (-1830…
Abstract Number: 1476 • 2018 ACR/ARHP Annual Meeting
Implication of CXCL5 (Epithelial neutrophil-activating peptide 78) in the Development of Insulin Resistance in Patients with Rheumatoid Arthritis
Sonia Peña¹, Beatriz-Segura Tejera², Raquel Lopez-Mejías³, De Vera-González AM⁴, Alejandra Gonzalez-Delgado⁵, Miguel Angel González-Gay⁶ and Iván Ferraz-Amaro⁷, ¹Rheumatology, Servicio de Reumatología, Hospital Universitario de Canarias,Spain, La Laguna, Spain, ²Rheumatology Division, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ³Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain, Santander, Spain, ⁴Division of Central Laboratory. Hospital Universitario de Canarias, San Cristobal de La Laguna, Spain, ⁵Division of Central Laboratory. Hospital Universitario de Canarias., Tenerife, Spain, ⁶Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL and School of Medicine, University of Cantabria, Santander, Spain, Santander, Spain, ⁷Division of Rheumatology, Hospital Universitario de Canarias, Tenerife, Spain, Tenerife, Spain
Background/Purpose: The chemokine molecule CXCL5 (C-X-C motif chemokine ligand 5, also known as epithelial neutrophil activating peptide 78 -ENA78-) constitutes a link between obesity, inflammation…
Abstract Number: 2763 • 2018 ACR/ARHP Annual Meeting
Utility of Serum Free Light Chains, Antiphospholipid Antibodies, and Cytokines in Giant Cell Arteritis
Matthew J. Koster¹, Melissa Snyder², Michel Villatoro-Villar¹, Cynthia S. Crowson³, Tanaz A. Kermani⁴ and Kenneth J. Warrington⁵, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, MN, ³Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ⁴Medicine, Division of Rheumatology, David Geffen School of Medicine, UCLA, Los Angeles, CA, ⁵Rheumatology, Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN
Background/Purpose: To investigate the utility of serum free light chains (FLC), antiphospholipid antibodies (APL), and cytokines in the evaluation of patients with biopsy-proven giant cell…
Abstract Number: 105 • 2018 ACR/ARHP Annual Meeting
Immunologic Properties of Cutaneous Lupus Erythematosus (CLE) Patients Refractory to Antimalarials Compared to Patients That Respond to Antimalarials
Majid Zeidi^1,2, Krisha Desai^3,4, Hee Joo Kim^3,4,5 and Victoria P. Werth^3,4, ¹University of Pennsylvania, Philadelphia, PA, ²Philadelphia Veterans Affairs Medical Center, Philadelphia, PA, ³Department of Dermatology, Corporal Michael J. Crescenz VAMC, Philadelphia, PA, ⁴Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁵Department of Dermatology, Gachon Gil Medical Center, School of Medicine, Gachon University, Incheon, Korea, Republic of (South)
Background/Purpose: Two major therapies for cutaneous lupus erythematosus (CLE) are the antimalarials, hydroxychloroquine (HCQ) and quinacrine (QC). HCQ is often the first-line therapy for CLE,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].